Drug intelligence / Profile preview

bimatoprost + timolol ocular insert

Development stage
Phase 4
Lead developer
Allergan
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

The bimatoprost + timolol ocular insert is a sustained-release drug delivery system developed by ForSight Vision5 (later acquired by Allergan) for the treatment of open-angle glaucoma and ocular hypertension. The device is a non-invasive, preservative-free peri-ocular ring that rests in the conjunctival fornix, providing continuous elution of both active ingredients over several weeks. Bimatoprost, a prostaglandin analog, lowers intraocular pressure by increasing uveoscleral outflow through the activation of prostaglandin F receptors. Timolol, a non-selective beta-adrenergic antagonist, complements this effect by reducing the production of aqueous humor in the ciliary body. This combination approach aims to improve patient compliance by replacing daily eye drops with a long-acting insert.

Other names
Fixed Combination Bimatoprost/Timolol Ocular InsertHelios combination ringBimatoprost/Timolol Ring
02

Targets

ADRB1 (β1)ADRB2 (β2)PTGER (Prostaglandin E2 receptor)PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on bimatoprost + timolol ocular insert.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bimatoprost + timolol ocular insert.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call